Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal JunctionJin Li, Hao Yu, Wei Liu et al.|Journal of Clinical Oncology|2016Cited by 1k
Targeting KRAS-mutant stomach/colorectal tumors by disrupting the ERK2-p53 complexXiang Wang, Jing‐Yu Lang, Qing Xie et al.|Cell Reports|2023Cited by 11
Targeting KRAS-mutant stomach/colorectal tumours by disrupting the ERK2-p53 complexXiang Wang, Jing‐Yu Lang, Qing Xie et al.|bioRxiv (Cold Spring Harbor Laboratory)|2020Cited by 0